top_image

Management Team

Peng Liang, Ph.D.
Founder, Chairman & President


 



  • Inventor of Trimer-Tag and Differential Display technology platforms; discovered IL-24 and its receptors (licensed to Wyeth/Pfizer)
  • Published 75+ original research papers in peer-reviewed journals (including Science, Nature Biotechnology, etc.), with over 10,000 citations
  • Winner of 1998 Molecular Bioanalytics Prize from the German Society of Biological Chemistry & Molecular Biology
  • Founder and President of GenHunter Corporation
  • Assoc. Professor Cancer Biology, Vanderbilt University
  • Postdoc, Harvard Medical School under Dr. Arthur Pardee
  • PhD in Biochemistry, University of Illinois / BS in Biology, Beijing University


Joshua Liang
Chief Executive Officer (CEO)

 



 

  • Oversee company operations & strategy; since joining Clover in 2016, raised over RMB 1.5 billion (>US$ 200 mm) in total capital, grew FTE headcount from 20 to 280+, initiated Clover’s first clinical trials in Australia & China, and lead partnership activities (CEPI, GSK, Dynavax, etc.)
  • Former investment banker at Centerview Partners; worked on >US$ 20 billion in transactions
  • Trained in biologic research; published 7 original research papers in peer-reviewed journals
  • BS in Economics, The Wharton School / BA in Biology, University of Pennsylvania
  • Roy & Diana Vagelos Program in Life Sciences & Management



 Htay Htay Han  MBBS
  
Chief Medical Officer, Vaccines (CMO)


 



  • Head of Early Clinical Development Programs at Takeda Vaccines
  • 23+ years at GSK Vaccines, including serving as Senior Director, Program Clinical R&D Lead
  • Bachelor of Medicine/Surgery, Medical University 1, Yangon, Myanmar



 Min Dong, Ph.D.
 EVP, Global Clinical Development

 



 
 
  • SVP Clinical Development at EOC Pharma
  • 10 years at Novartis (Shanghai & Basel), serving as Director of Global Program Team in the Oncology Translational Medicine (OTM) unit
  • PhD, Molecular & Systems Toxicology/ Pharmacology, MIT
  • MS, Molecular Biophysics, Tsinghua Univ.



  David He, PhD
 
Chief Technical Officer (CTO)

 
 



 
  • VP Technical Operations & Head of China Manufacturing Site at Legend Biotech
  • Head of CS&T & Member of Site Leadership Team, Boehringer-Ingelheim (BI)
  • Postdoc, University of Alabama  at Birmingham (UAB)
  • PhD in Molecular Biology, Sun Yat-Sen University
 

 

 Xiaobing Li   PhD MBA
  
EVP, Product Development & Portfolio Mgmt

 



 
  • VP, Head of Program Mgmt, Voyager Therap.
  • Senior Director, Global Program Lead at Sage Therapeutics and Ironwood Pharmaceuticals
  • Program Director/Leader at Alkermes
  • 15 years at Janssen (JNJ), incl. Director of Compound Mgmt Team
  • PhD in Heterocyclic/Organic Chemistry, Princeton University


 

  Jian Ren   
  
SVP, Quality

 



 
  • Head of Quality, Boehringer Ingelheim (China)
  • Associate Quality Director, Roche
  • Produce Assessor & GMP Inspector, Health Sciences Authority (Singapore)
  • Quality/QC/QA at MSD, GSK & Pfizer
  • MS, Microbiology, Liaoning N. University



  Andy Chin   MBA
  
VP, Biomanufacturing / Changxing Site GM


 



 
  • Senior Production Director at Legend Biotech
  • Head of Production, Boehringer-Ingelheim (BI)
  • Prior to joining BI, worked for various biopharma and CDMO companies, including Baxalta, Lonza, MSD Singapore and Wyeth Nutritional
  • MBA, University of S. Queensland (Australia)
  • Bachelor, University of Portsmouth


 

   Steven Gong  MBA
 
VP, Business Development & Strategy

 

 
 

 
  • Senior Director, BD at Eddingpharm
  • Assoc. Director, Strategic Marketing, Novartis
  • Strategic Dev. Manager (Diabetes) at Sanofi
  • Additional experience at B.Braun, Fresenius Medical Care and Medtronic
  • MBA, CEIBS (MBA exchange at Indiana University Bloomington)

 
 

 Cindy Min 
 
VP, Public Affairs

 



 
  • Head of Communications, Novartis China (also Head of Health Policy Research, Public Affairs)
  • Head of Corporate Communications & Public Affairs, Janssen China
  • Head of Healthcare Business, Ogilvy China
  • ML, Diplomacy, Renmin University
  • BS, Pharmacy, Peking University



 Zheng Ping   
 
Director, Operations







  • Former CEO of Hui Cheng Pharmaceuticals, where he oversaw launches of several small molecule drugs
  • Former VP, Sichuan Industrial Institute of Antibiotics
  • BS in Biology, Sichuan University




 
Scientific Advisory Board


 Xiaodong Wang, Ph.D. 
 Founding Advisor, Board Director

 


 

  • Founder of BeiGene (Nasdaq: BGNE) since 2010, and Chairman of Scientific Advisory Board since 2011
  • Founding Director & Architect of 700-person team at the National Institute of Biological Sciences (NIBS) in Beijing (2003-present)
  • Howard Hughes Medical Institute Investigator, George L. MacGregor Distinguished Chair in Biomedical Sciences (1997-2010) and Professor in Biomedical Sciences (2001-2010) at University of Texas Southwestern Medical Center
  • Member of National Academy of Sciences, USA
  • Foreign associate of Chinese Academy of Sciences
  • Founder of Joyant Pharmaceuticals, venture capital-backed oncology biotech in US
  • PhD in Biochemistry from University of Texas Southwestern Medical Center
  • BS in Biology from Beijing Normal University



  Jianwei Zhu, Ph.D., MBA
   
Founding Advisor, Board Director


 

 



  • President & CEO, Jecho Biopharmaceuticals
  • Director of Biopharma Development Program, SAIC-Frederick
  • Dean, School of Pharmacy, Shanghai Jiao Tong University
  • Consultant to International Vaccine Institute, US NIH, Boehringer Ingelheim, Talecris, Cytogenix
  • MBA, Hood Business School
  • Postdoc, MIT & Harvard Medical School
 


 Jinyou Zhang, Ph.D.
 Scientific Advisory Board – Biomanufacturing

 




  • Head of Bioprocess Development & Manufacturing, BeiGene
  • Over 24 years of industry experience in bioprocessing and biomanufacturing
  • Well-established in developing culture media and upstream processes
  • Published 40 original research papers in peer-reviewed journals (lead author on 24)
  • Former Vice President and Site Head of Biomanufacturing at WuXi AppTec
  • Vice President of Process Development and Manufacturing at Immunomedics in Morris Plains, NJ
  • Executive Director of Bioprocess R&D at Novavax
  • Senior Investigator with 15 years development experience at Bioprocess R&D, Merck
  • PhD in Biochemical Engineering from Massachusetts Institute of Technology in 1991 under supervision of Professor Arnold Demain (Fellow of U.S. Academy of Science, Ex-President of Society of Industrial Microbiology)



  Shun Luo, Ph.D.
  
Scientific Advisory Board – Process Development

 




  • President, Jianshun Biosciences
  • Former Scientific Director in Cell Science & Process Development, Amgen
  • Former Media Group Leader, Genentech
  • Former R&D Head, JRH Biosciences
  • Former Research Scientist, Ares Serono
  • Postdoc, Harvard Medical School
  • PhD in Microbiology & Immunology, Virginia Tech
 


 

 Karl Zhou, Ph.D.
 
Scientific Advisory Board – Clinical Development

 





  • 20+ years of clinical development experience at global leading pharmaceutical and CRO companies, with a focus on oncology drugs
  • Oversaw early and late stage clinical development of world's first approved immuno-oncology antibody Yervoy (ipilimumab) targeting CTLA-4
  • Previously served as Senior Medical Director and Clinical Lead at inVentiv Health, AstraZeneca, Pfizer, Baxter International and Schering-Plough
  • Clinical Fellowship, Dana-Farber Cancer Institute
  • Postdoc, Harvard Medical School under Dr. Emil Frei III
  • PhD, Baylor College of Medicine